Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer

Combined Inhibition of IGF-1R/IR and Src Family Kinases Enhances Antitumor Effects in Prostate Cancer by Decreasing Activated Survival Pathways

(2012) Farshid Dayyani et al.   PLoS One

Dasatinib combined with docetaxel for castration-resistant prostate cancer

(2011) John C. Araujo et al.   CANCER

Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors

(2011) J. C. Montero et al.   CLINICAL CANCER RESEARCH

Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer

(2011) F. Dayyani et al.   JNCI-Journal of the National Cancer Institute

Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer

(2011) Evan Y. Yu et al.   UROLOGY

Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts

(2010) Y-C Lee et al.   ONCOGENE

Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

(2009) E. Y. Yu et al.   CLINICAL CANCER RESEARCH

The Role of Liver-Derived Insulin-Like Growth Factor-I

(2009) Claes Ohlsson et al.   ENDOCRINE REVIEWS

Targeting Src Family Kinases Inhibits Growth and Lymph Node Metastases of Prostate Cancer in an Orthotopic Nude Mouse Model

(2008) S. I. Park et al.   CANCER RESEARCH